Table 3 Putative core genes and functional targets with disease association.

From: Tissue-specific multi-omics analysis of atrial fibrillation

   

Protein AF association

Gene

Chr

Type

β

T-value

P-value

FDR

TNNT2a,d

chr1

Trans-eQTL

−0.0609

−1.61

0.113

1.00

NKX2-5b

chr5

Trans-eQTL

    

CYB5R3

chr22

Trans-pQTL

−0.0212

−0.662

0.511

1.00

NDUFB3c

chr2

Trans-pQTL

−0.0631

−1.35

0.182

1.00

HIBADH

chr7

Trans-pQTL

−0.0454

−1.24

0.218

1.00

NDUFA9d

chr12

Trans-pQTL

−0.0533

−1.20

0.235

1.00

DLAT

chr11

Trans-pQTL

−0.0231

−0.579

0.564

1.00

PPIF

chr10

NKX2-5 target

−0.0342

−1.13

0.261

1.00

MYL4b,d

chr17

NKX2-5 target

−0.0270

−0.664

0.509

1.00

CKMd

chr19

NKX2-5 target

−0.0875

−2.78

0.00705

0.120

MYL7

chr7

NKX2-5 target

−0.0421

−1.04

0.304

1.00

PGAM2d

chr7

NKX2-5 target

−0.175

−3.70

0.000452

0.00813

TNNC1a

chr3

NKX2-5 target

−0.0557

−1.71

0.0929

1.00

CYC1

chr8

NKX2-5 target

−0.0946

−2.14

0.036

0.545

ETFBb,d

chr19

NKX2-5 target

−0.0553

−1.65

0.105

1.00

PRDX5

chr11

NKX2-5 target

−0.0524

−1.79

0.0789

1.00

AK1

chr9

NKX2-5 target

−0.0669

−2.17

0.0341

0.545

ALDOAd

chr16

NKX2-5 target

−0.0646

−2.17

0.0341

0.545

TCAPa

chr17

NKX2-5 target

−0.0178

−0.282

0.779

1.00

TOM1L2

chr17

NKX2-5 target

−0.0771

−1.75

0.0849

1.00

  1. Proteomics differential abundance results in human atrial appendage tissue for prevalent AF. Two-sided t-tests were calculated as part of a multiple linear regression model including AF-related covariates sex, age, BMI, diabetes, systolic blood pressure, hypertension medication, myocardial infarction and smoking status (see methods differential protein analysis, N = 78, df = 66). The Benjamini-Hochberg procedure was used to asses FDR and account for multiple comparisons.
  2. AF atrial fibrillation, BMI body mass index, QTL quantitative trait loci, FDR false discovery rate.
  3. aMutation known to affect cardiovascular phenotypes.
  4. bMutation known to affect arrhythmias.
  5. cDifferential expression or functional impairment for cardiovascular phenotypes.
  6. dDifferential expression or functional impairment for arrhythmias.